# Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

> **NCT04980482** · PHASE2 · COMPLETED · sponsor: **Arbutus Biopharma Corporation** · enrollment: 43 (actual)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** AB-729
- **DRUG:** Peg-IFNα-2a

## Key facts

- **NCT ID:** NCT04980482
- **Lead sponsor:** Arbutus Biopharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-29
- **Primary completion:** 2025-03-13
- **Final completion:** 2025-05-21
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04980482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04980482, "Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04980482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*